Product Description
Sodium thiosulphate (STS), an antioxidant and calcium chelating agent, has been used for the treatment of calciphylaxis. However, its efficacy and safety have not been systematically analysed and evaluated. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/28603903/)
Mechanisms of Action: Cyanide Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Bangladesh | Belgium | Chile | China | Colombia | Dominican Republic | European Medicines Agency | France | Germany | Greece | Hong Kong | Iceland | India | Lithuania | Malaysia | New Zealand | Russia | Slovakia | Spain | Sweden | Taiwan | Thailand | United Kingdom | United States | Vietnam
Approved Indications: Oncology Solid Tumor Unspecified | Oncology Unspecified
Known Adverse Events: Hypernatremia | Hypokalemia
Company: American Regent
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, France, Germany, Italy, Netherlands, Spain, United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Dermatitis, Allergic Contact|Dermatitis, Atopic|Dermatitis, Contact
Phase 2: Breast Cancer|Dermatomyositis|Head and Neck Cancer|Hypopharyngeal Cancer|Laryngeal Cancer|Mouth Cancer|Oropharyngeal Cancer|Papilloma|Scleroderma, General|Squamous Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2023-507972-35-01 | P3 |
Unknown Status |
Dermatitis, Allergic Contact|Dermatitis, Contact |
2026-01-01 |
|
| 2023-507972-35-00 | P3 |
Unknown Status |
Dermatitis, Atopic|Dermatitis, Allergic Contact|Dermatitis, Contact |
2026-01-01 |
|
| NCI-2020-05752 | P2 |
Completed |
Hypopharyngeal Cancer|Squamous Cell Carcinoma|Mouth Cancer|Head and Neck Cancer|Oropharyngeal Cancer|Laryngeal Cancer|Papilloma |
2023-05-31 |
|
| BYON5667.002 | P2 |
Completed |
Breast Cancer |
2023-04-19 |
57% |
| BYON5667.002 | P2 |
Completed |
Breast Cancer |
2023-04-19 |
57% |